Literature DB >> 16750686

Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol.

Markus Exner1, Erich Minar, Wolfgang Mlekusch, Schila Sabeti, Jasmin Amighi, Wolfgang Lalouschek, Gerald Maurer, Christian Bieglmayer, Heidi Kieweg, Oswald Wagner, Martin Schillinger.   

Abstract

OBJECTIVES: We investigated the effect of myeloperoxidase (MPO) on progression of carotid stenosis in states of high and low high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) levels.
BACKGROUND: Myeloperoxidase is pivotally involved in the pathogenesis of atherosclerosis. In vitro data suggest that MPO exerts deleterious effects via oxidative modulation of lipoproteins.
METHODS: We prospectively studied 1,019 of 1,268 consecutive patients who were asymptomatic with respect to carotid artery disease. Patients underwent serial carotid ultrasound investigations at baseline and after a follow-up interval of median 7.5 months (range 6 to 9 months), categorizing carotid arteries as 0% to 29%, 30% to 49%, 50% to 69%, 70% to 89%, or 90% to 99% stenosed or occluded. The MPO, HDL-C, and LDL-C levels were measured at baseline, grouped by medians, and correlated with progression of carotid atherosclerosis.
RESULTS: Progression of carotid atherosclerosis was found in 100 of 1,019 patients (9.8%). Myeloperoxidase (p = 0.014) but not HDL-C (p = 0.95) or LDL-C (p = 0.30) were associated with progressive disease. However, MPO > or =310 ng/ml was significantly associated with progressive disease (adjusted odds ratio [OR] 2.57, 95% confidence interval [CI] 1.39 to 4.75) only in patients with HDL-C levels <49 mg/dl. Otherwise, in patients with higher HDL-C levels (> or =49 mg/dl), MPO > or =310 ng/ml did not predict disease progression (adjusted OR 1.42, 95% CI 0.72 to 2.78). No interaction of MPO with LDL-C was observed.
CONCLUSIONS: Myeloperoxidase was associated with progression of carotid atherosclerosis in patients with HDL cholesterol levels below 49 mg/dl.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750686     DOI: 10.1016/j.jacc.2006.01.067

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Unraveling mechanisms of toxicant-induced oxidative stress in cardiovascular disease.

Authors:  Tammy R Dugas
Journal:  Curr Opin Toxicol       Date:  2017-10-12

2.  Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome.

Authors:  P Gururajan; P Gurumurthy; P Nayar; S Babu; A Sarasabharati; D Victor; K M Cherian
Journal:  Heart Asia       Date:  2009-01-01

Review 3.  Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?

Authors:  Daniele Pastori; Roberto Carnevale; Pasquale Pignatelli
Journal:  Intern Emerg Med       Date:  2013-09-22       Impact factor: 3.397

4.  Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study.

Authors:  Lu Q Chen; Anand Rohatgi; Colby R Ayers; Sandeep R Das; Amit Khera; Jarett D Berry; Darren K McGuire; James A de Lemos
Journal:  Atherosclerosis       Date:  2011-08-22       Impact factor: 5.162

5.  Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase.

Authors:  Anna Klinke; Eva Berghausen; Kai Friedrichs; Simon Molz; Denise Lau; Lisa Remane; Matthias Berlin; Charlotte Kaltwasser; Matti Adam; Dennis Mehrkens; Martin Mollenhauer; Kashish Manchanda; Thorben Ravekes; Gustavo A Heresi; Metin Aytekin; Raed A Dweik; Jan K Hennigs; Lukas Kubala; Erik Michaëlsson; Stephan Rosenkranz; Tanja K Rudolph; Stanley L Hazen; Hans Klose; Ralph T Schermuly; Volker Rudolph; Stephan Baldus
Journal:  JCI Insight       Date:  2018-06-07

6.  The Atherogenic Index of Plasma is Independently Associated with Symptomatic Carotid Artery Stenosis.

Authors:  Ravi Garg; Natalie Knox; Supritha Prasad; Shuchi Zinzuwadia; Megan A Rech
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-10-09       Impact factor: 2.136

7.  Risk factor correlates of platelet and leukocyte markers assessed by flow cytometry in a population-based sample.

Authors:  Aaron R Folsom; Nena Aleksic; Antonio Sanhueza; Eric Boerwinkle
Journal:  Atherosclerosis       Date:  2008-11-18       Impact factor: 5.162

8.  Cardiovascular Complications in CKD Patients: Role of Oxidative Stress.

Authors:  Elvira O Gosmanova; Ngoc-Anh Le
Journal:  Cardiol Res Pract       Date:  2011-01-02       Impact factor: 1.866

9.  A low-frequency variant in MAPK14 provides mechanistic evidence of a link with myeloperoxidase: a prognostic cardiovascular risk marker.

Authors:  Dawn M Waterworth; Li Li; Robert Scott; Liling Warren; Christopher Gillson; Jennifer Aponte; Lea Sarov-Blat; Dennis Sprecher; Josée Dupuis; Alex Reiner; Bruce M Psaty; Russell P Tracy; Honghuang Lin; Ruth McPherson; Stephanie Chissoe; Nick Wareham; Margaret G Ehm
Journal:  J Am Heart Assoc       Date:  2014-08-27       Impact factor: 5.501

Review 10.  Biochemical and pathological studies on peroxidases -an updated review.

Authors:  Amjad A Khan; Arshad H Rahmani; Yousef H Aldebasi; Salah M Aly
Journal:  Glob J Health Sci       Date:  2014-05-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.